Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

BACKGROUND: A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected in indi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Skaga, Erlend, Kulesskiy, Evgeny, Fayzullin, Artem, Sandberg, Cecilie J., Potdar, Swapnil, Kyttälä, Aija, Langmoen, Iver A., Laakso, Aki, Gaál-Paavola, Emília, Perola, Markus, Wennerberg, Krister, Vik-Mo, Einar O.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593575/
https://ncbi.nlm.nih.gov/pubmed/31238897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5861-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars